Biomarcadores inflamatórios na Depressão Maior: uma revisão sistemática
DOI:
https://doi.org/10.34024/rnc.2023.v31.14730Palavras-chave:
Depressão, Inflamação, BiomarcadoresResumo
Introdução. O Transtorno Depressivo Maior (TDM) é um tipo de desordem de humor que envolve a interação entre agentes de natureza psicossocial, genética e biológica. Caracteriza-se principalmente por tristeza persistente, anedonia e incapacidade de realizar atividades diárias. O TDM é um dos principais transtornos mentais que contribui para a carga global de doenças, além de ser subdiagnosticado e subtratado. Dentre os principais problemas relacionados ao diagnóstico e tratamento da depressão estão seu alto nível de subjetividade e sua heterogeneidade. Nesse contexto, os biomarcadores são medidas biológicas quantitativas e/ou qualitativas que se relacionam fisiopatologicamente com um desfecho clínico, e podem auxiliar na melhoria de alternativas terapêuticas e diagnósticas para transtornos mentais. Objetivo. Reconhecer biomarcadores inflamatórios e associados a inflamação no TDM, na literatura científica. Método. Foram utilizadas as bases de dados PubMed, Scopus e Scielo. Resultados. Foram vistos achados moleculares correlacionados significativamente com o diagnóstico e a sintomatologia, que não foram observados em grupos controle ou grupo com remissão da depressão. Foram relatadas alterações quantitativas nas citocinas IL-6, IL-15, IL-21, IL-23, IL-35, IL-17, IL-1β, TNF-α, IFN-γ, em supressores de sinalização de citocinas, em fatores de crescimento e correlações significativas entre inflamação e estresse oxidativo. Também há relatos de perturbações em gêneros bacterianos pertencentes ao filo Firmicutes. Conclusão. A caracterização de biomarcadores inflamatórios surge como alternativa para novas hipóteses neurobiológicas da TDM. Os biomarcadores contribuem com tratamentos mais seletivos e eficazes que possam prevenir o aparecimento ou melhor tratar essa neuropatologia, além de auxiliarem na detecção precoce de tentativas de suicídio.
Downloads
Métricas
Biografia do Autor
Celina Cavalcante Muniz Gomes, UFPE
Referências
Bains N, Abdijadid S, Miller JL. Major Depressive Disorder (Nursing). Treasure Island (FL): StatPearls Publishing 2021. https://www.ncbi.nlm.nih.gov/books/NBK570554
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global Burden of 369 Diseases and Injuries in 204 Countries and territories, 1990–2019: a Systematic Analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9
Faisal-Cury A, Ziebold C, Rodrigues DMO, Matijasevich A. Depression underdiagnosis: Prevalence and associated factors. A population-based study. J Psychiatr Res 2022;151:157–65. https://doi.org/10.1016/j.jpsychires.2022.04.025
Manual Diagnóstico e Estatístico de Transtornos Mentais: DSM-5. 5. ed. Porto Alegre: Artmed, 2014.
Leonard BE. The Concept of Depression as a Dysfunction of the Immune System. Mod Trends Pharmacopsychiatr 2010;53–71. https://doi.org/10.1159/000319504
García-Gutiérrez MS, Navarrete F, Sala F, Gasparyan A, Austrich-Olivares A, Manzanares J. Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality. Front Psychiatr 2020;11:432. https://doi.org/10.3389/fpsyt.2020.00432
Blackburn TP. Depressive disorders: Treatment failures and poor prognosis over the last 50 years. Pharmacol Res Perspec 2019;7:e00472. https://doi.org/10.1002/prp2.472
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. FOCUS 2018;16:420–9. https://doi.org/10.1176/appi.focus.16407
Choi H, Mun S, Joo E-J, Lee KY, Kang H-G, Lee J. Serum proteomic analysis of major depressive disorder patients and their remission status: Novel biomarker set of zinc-alpha-2-glycoprotein and keratin type II cytoskeletal 1. Inter J Biol Macromol 2021;183:2001–8. https://doi.org/10.1016/j.ijbiomac.2021.05.172
Cosgrove KT, Burrows K, Avery JA, Kerr KL, DeVille DC, Aupperle RL, et al. Appetite change profiles in depression exhibit differential relationships between systemic inflammation and activity in reward and interoceptive neurocircuitry. Brain Behav Imm 2020;83:163–71. https://doi.org/10.1016/j.bbi.2019.10.006
Doolin K, Farrell C, Tozzi L, Harkin A, Frodl T, O’Keane V. Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder. Inter J Mol Sci 2017;18:2226. https://doi.org/10.3390/ijms18102226
Garrosa-Jiménez J, Sánchez Carro Y, Ovejero-Benito MC, del Sastre E, García AG, López MG, et al. Intracellular calcium and inflammatory markers, mediated by purinergic stimulation, are differentially regulated in monocytes of patients with major depressive disorder. Neurosci Letters 2021;765:136275. https://doi.org/10.1016/j.neulet.2021.136275
Grudet C, Wolkowitz OM, Mellon SH, Malm J, Reus VI, Brundin L, et al. Vitamin D and inflammation in major depressive disorder. J Affec Dis 2020;267:33–41. https://doi.org/10.1016/j.jad.2020.01.168
Han K-M, Tae W-S, Kim A, Kang Y, Kang W, Kang J, et al. Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain Behav Imm 2020;87:852–9. https://doi.org/10.1016/j.bbi.2020.03.021
Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Imm 2012;26:979–87. https://doi.org/10.1016/j.bbi.2012.05.010
Kobayashi N, Shinagawa S, Nagata T, Shigeta M, Kondo K. Suppressors of Cytokine Signaling Are Decreased in Major Depressive Disorder Patients. J Personal Med 2022;12:1040. https://doi.org/10.3390/jpm12071040
Kuwano N, Kato TA, Mitsuhashi M, Sato-Kasai M, Shimokawa N, Hayakawa K, et al. Neuron-related blood inflammatory markers as an objective evaluation tool for major depressive disorder: An exploratory pilot case-control study. J Affec Dis 2018;240:88–98. https://doi.org/10.1016/j.jad.2018.07.040
Maes M, Rachayon M, Jirakran K, Sodsai P, Klinchanhom S, Gałecki P, et al. The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach. Cells 2022;11:1183. https://doi.org/10.3390/cells11071183
Nowak W, Grendas LN, Sanmarco LM, Estecho IG, Arena AR, Eberhardt N, et al. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. EBioMed 2019;50:290-305. https://doi.org/10.1016/j.ebiom.2019.10.063
Pasquali MA, Harlow BL, Soares CN, Otto MW, Cohen LS, Minuzzi L, et al. A longitudinal study of neurotrophic, oxidative, and inflammatory markers in first-onset depression in midlife women. Eur Arc Psychiatr Clin Neurosci 2017;268:771–81. https://doi.org/10.1007/s00406-017-0812-z
Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Imm 2006;20:169–74. https://doi.org/10.1016/j.bbi.2005.05.004
Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res 2018;8:57. https://doi.org/10.1186/s13550-018-0401-9
Savitz J, Dantzer R, Meier TB, Wurfel BE, Victor TA, McIntosh SA, et al. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinol 2015;62:54–8. https://doi.org/10.1016/j.psyneuen.2015.07.609
Scaini G, Mason BL, Diaz AP, Jha MK, Soares JC, Trivedi MH, et al. Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role? Mol Psychiatr 2021;27:1095–102. https://doi.org/10.1038/s41380-021-01312-w
Tseng P-T, Cheng Y-S, Chen Y-W, Wu C-K, Lin P-Y. Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis. Eur Neuropsychopharmacol 2015;25:1622–30. https://doi.org/10.1016/j.euroneuro.2015.06.001
Ye Q, Zhang Y, Zhang Y, Chen Z, Yu C, Zheng C, et al. Low VGF is associated with executive dysfunction in patients with major depressive disorder. J Psychiatr Res 2022;152:182–6. https://doi.org/10.1016/j.jpsychires.2022.06.030
Bai S, Xie J, Bai H, Tian T, Zou T, Chen J-J. Gut Microbiota-Derived Inflammation-Related Serum Metabolites as Potential Biomarkers for Major Depressive Disorder. J Inflamm Res 2021;14:3755–66. https://doi.org/10.2147/JIR.S324922
Colasanto M, Madigan S, Korczak DJ. Depression and Inflammation Among Children and Adolescents: A Meta-analysis. J Affec Dis 2020;277:940-8. https://doi.org/10.1016/j.jad.2020.09.025
Ma K, Zhang H, Baloch Z. Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci 2016;17:733. https://doi.org/10.3390/ijms17050733
Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 2014;140:774-815. https://doi.org/10.1037/a0035302
Meyrel M, Varin L, Detaint B, Mouaffak F. Le microbiote intestinal: un nouvel acteur de la dépression? L’Encéphale 2018;44:67–74. https://doi.org/10.1016/j.encep.2017.03.005
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Celina Cavalcante Muniz Gomes, Michelle Melgarejo da Rosa
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Aceito: 2023-04-12
Publicado: 2023-04-26
Português
English
Español
